Patent ID: 7071211

Claim:
A pharmaceutically acceptable composition useful to increase the activity of Gelatinase A in ocular cells comprising one or more compounds selected from the following formula: wherein W is selected from the group consisting of oxygen and sulfur; Z is selected from the group consisting of oxygen and sulfur; R 1 is a substituted or unsubstituted C 6-25 aryl wherein, when R 1 is substituted, R 1 is substituted with one or more substituents selected from the group consisting of C 1-25 alkyl, C 1-25 alkenyl, C 1-25 alkynyl, C 1-25 alkoxy, C 1-25 alkenoxy, hydroxy, carboxy, amino, C 1-25 (N-alkylcarbonyl)amino, C 1-25 (N-alkylcarbonyl)-N-alkylamino, C 1-25 (N-alkylcarbonylalkyl)amino, cyano, nitro, sulfo, sulfino, sulfhydryl, halo, C 1-25 haloalkyl, trifluoromethyl, C 1-25 trifluoromethylalkyl, C 6-30 arylalkyl, C 6-30 aryl, C 1-25 N-alkylamino, C 1-25 N-dialkylamino, C 1-25 (N-alkyl-N-alkenyl)amino, C 1-25 N-dialkenylamino, C 1-25 alkylsulfonyl, C 1-25 alkylsulfinyl, C 1-25 alkylthio, hydrido, C 1-25 cyanoalkyl, C 1-25 acyl, C 1-25 alkylcarbonyloxy, nitroso, C 1-25 alkoxyalkyl, C 1-25 alkoxycarbonyl, C 1-25 hydroxyalkyl, thiocarboxy, C 1-25 thiocarboxyalkyl, C 1-25 alkylthiocarbonyl, C 1-25 alkylthiocarbonylalkyl, C 1-25 alkoxythiocarbonyl, C 1-25 alkoxythiocarbonylalkyl, sulfamoyl, sulfinamoyl, C 1-25 N-alkylsulfamoyl, C 1-25 N-dialkylsulfamoyl, C 1-25 N-alkylsulfinamoyl, C 1-25 N-dialkylsulfinamoyl, C 1-25 sulfamoylalkyl, C 1-25 sulfinamoylalkyl, aminocarbonyl, C 1-25 aminocarbonylalkyl aminocarbonylmethyl, C 1-25 N-alkylaminocarbonyl, C 1-25 N-dialkylaminocarbonyl, C 1-25 alkoxycarbonylamino, thiocarbamoyl, C 1-25 thiocarbamoylalkyl, C 1-25 (N-alkyl)thiocarbamoyl, C 1-25 (N-dialkyl)thiocarbamoyl, aminothio, C 1-25 alkylaminothio, C 1-25 N-dialkylaminothio, C 1-25 cycloalkyl, C 1-25 cycloalkenyl, C 1-25 aryloxy, C 1-25 cycloalkoxy, C 1-25 cycloalkenoxy, N- or S-oxo and N- or S-thioxo; R 2 is branched or unbranched and substituted or unsubstituted selected from the group consisting of hydrido, C 1-10 alkyl, cyano, trifluoromethyl, C 6-15 cycloalkyl or C 6-30 aryl; R 3 and R 4 form a 4 or 5 membered ring with the N, containing no other heteroatom; and a pharmaceutically acceptable aqueous or non-aqueous carrier for delivery on or within the eye.